Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
Alexander M.M. Eggermont(University Medical Center Utrecht), Caroline Robert(Institut Gustave Roussy), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michal Kiciński(European Organisation for Research and Treatment of Cancer), Dirk Schadendorf(National Center for Tumor Diseases), Andrey Meshcheryakov(Russian Cancer Research Center NN Blokhin), Sandrine Marréaud(European Organisation for Research and Treatment of Cancer), Paul Lorigan(Manchester Academic Health Science Centre), Stéphane Dalle(Hospices Civils de Lyon), Dmitri Grebennik(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alexander C. J. van Akkooi(The University of Sydney), James Larkin(Trinity College Dublin), Susana Puig(Instituto de Salud Carlos III), Stefan Suciu(St James's University Hospital), Victoria Atkinson(The University of Queensland), Matteo S. Carlino(The University of Sydney), Christian U. Blank(The Netherlands Cancer Institute), Andrew Haydon(The Alfred Hospital), Rahima Jamal(Centre Hospitalier de l’Université de Montréal), Clemens Kreplere(Merck & Co., Inc., Rahway, NJ, USA (United States)), Georgina V Long(The University of Sydney), Anna Maria Di Giacomo(University of Siena), Marye J. Boers‐Sonderen(Radboud University Nijmegen), Jean-Jacques Grob(Aix-Marseille Université), Adnan Khattak(Edith Cowan University), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Alfonsus JM. van den Eertwegh(Amsterdam University Medical Centers), Shahneen Sandhu(Peter MacCallum Cancer Centre), Mario Mandalà(University of Perugia)
Cited by 84
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k